PTPRC and leukemia: To investigate the anti-leukemia efficacy of MYBMIM, we engrafted sublethally irradiated NOD-scid IL2Rγnull (NSG) mice with primary patient-derived MLL-rearranged human leukemia cells, with their detailed characterization described in Supplementary Table 3, and determined leukemia development using peripheral blood flow cytometry for human-specific CD45 (hCD45).